Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction
Vaneet Jearath1, Rajan Vashisht1, Vipul Rustagi1, Sujeet Raina1★, Rajesh Sharma1★ Corresponding author
- 1Department of Medicine, Dr. Rajendra Prasad Government Medical College, Tanda, Himachal Pradesh, India.
CORRESPONDENCE
Sujeet Raina
Department of Medicine, Dr. Rajendra Prasad Government Medical College, Tanda, Himachal Pradesh, India.
Received: 30-12-2014; Revised: 20-03-2015; Accepted: 08-08-2015.
Volume 7, Issue 1 · pp. 41–3 · PUBLISHED 2016 · DOI: 10.4103/0976-500X.179363
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Pioglitazone‑induced heart failure is known in patients with underlying heart disease, but is not well documented in patients with normal left ventricular function. Pioglitazone has been very popular as it is an insulin sensitizer and insulin resistance is prevalent among Indians. Fluid retention exacerbates pre‑existing heart failure or precipitates heart failure in a patient with underlying left ventricular dysfunction. However, pathogenesis of heart failure in a patient with normal left ventricular function is not known. Probably it is due to dose‑related effect on pulmonary endothelial permeability, rather than alterations in left ventricular mass or ejection fraction. We report a patient who developed congestive heart failure and pulmonary edema with normal left ventricular function within 1 year of starting pioglitazone therapy. We have to be careful in monitoring all possible side effects during followup when patients are on pioglitazone therapy.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Jearath, V., Vashisht, R., Rustagi, V., Raina, S., & Sharma, R. (2016). Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction. Journal of Pharmacology and Pharmacotherapeutics, 7(1), 41–3. https://doi.org/10.4103/0976-500X.179363